Emily Cowley Leongini Questions Administration’s Stance on FDA Oversight Post-Court Ruling
Law360
Partner Emily Cowley Leongini was quoted on the federal court decision regarding the oversight of laboratory-developed tests by the US Food and Drug Administration.
Emily said, “I think that’d be a pretty difficult jurisdictional issue that I don’t know how the FDA would be able to get around,” in reference to the Trump administration’s options following the court’s ruling.
She further noted that Judge Jordan’s decision should be considered a “data point” in the evolving case law landscape after the Supreme Court’s Loper Bright decision in 2024.
Read the full article here. (Subscription required)
Contacts
- Related Practices